HEALTH POLICY: Addressing conflicts of interest of public speakers at advisory committee meetings

    loading  Checking for direct PDF access through Ovid

Abstract

A study reveals that, from 2009-2014, a considerable percentage of public speakers at Oncologic Drugs Advisory Committee meetings had disclosed or undisclosed financial associations with the drug company seeking product approval. Amid calls for increased public engagement in health care and health-care research, steps must be taken to minimize the conflicts of interests of those who claim to speak for patients and the public.

Related Topics

    loading  Loading Related Articles